- active not recruitingPHASE2
Seal, Stopping Eczema and Allergy Study
This study is for babies under 12 weeks old with early eczema. It compares special skin creams and treatments to standard care to see if they can reduce eczema and prevent food allergies. We want to find the best ways to keep young skin healthy.
United States · United Kingdom - recruitingPHASE2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
This study is testing a new medicine, Galvokimig, for adults with moderate to severe eczema (atopic dermatitis). We want to find the best dose and check how well it works and if it's safe compared to a dummy drug.
United States · Bulgaria · Canada - recruitingPHASE3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
This study looks at a new drug called Tralokinumab for children and babies with moderate to severe eczema. We want to see if it's safe and helps when given with standard eczema creams. It could offer new hope for managing this condition.
United States · Belgium · Canada - active not recruitingPHASE3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
This study looks at a new combination treatment for teenagers and adults with moderate to severe eczema. It combines a new tablet called upadacitinib with steroid creams to see how well it works and if it's safe.
United States · Australia · Austria - active not recruitingPHASE3
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
This study looks at the long-term safety of a treatment called dupilumab for children and teenagers with eczema (atopic dermatitis). It also checks how well it works and how the body handles the medicine over time. There's an optional part looking at a new way to give the medicine.
United States · Canada · Czechia - recruitingPHASE3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
This study is testing a new cream called Ruxolitinib for children and teenagers aged 6 to 17 who have moderate eczema (atopic dermatitis). We want to see if it's safe and effective at reducing their skin symptoms. There's also a 'dummy' cream for comparison.
United States · Belgium · Canada - recruiting
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
This study, called 'Mind and Skin,' looks at how severe eczema affects the brain, mental health, and thinking abilities in young people aged 12-18. It examines links between inflammation, itching, disturbed sleep, and how new eczema treatments might help.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
18424-326: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is testing a new cream called ruxolitinib for adults with moderate eczema. It aims to see if the cream helps reduce eczema symptoms and itching by comparing it to a cream with no medicine. Researchers will check results after 8 weeks.
Spain · Italy · Poland - authorisedTherapeutic exploratory (Phase II)
C6231002 - A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
This study is looking into a new medication for adults with moderate to severe eczema. It wants to see how well it works and if it's safe. Some people will get the new medicine, and others will get a dummy medicine to compare the effects.
Poland · Czechia · Germany - active not recruitingPHASE2
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
This study looks at new treatments for moderate to severe eczema (atopic dermatitis). It checks how well a drug called Lutikizumab works, either alone or with other treatments, and if it's safe. Participants will get injections and have regular check-ups.
United States · Japan · South Korea - active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
This study is testing a new medicine, baricitinib, for children and teenagers aged 2 to 17 with moderate to severe eczema. Researchers want to see if it's safe and helps improve their skin compared to a dummy pill or usual treatments.
Argentina · Australia · Austria - recruitingPHASE3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study looks at two medicines, upadacitinib and dupilumab, for children aged 2 to 11 with moderate to severe eczema (atopic dermatitis). It wants to see which one works better and has fewer side effects for children who need strong treatment.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Poland · Estonia · Denmark - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
This study is testing a new medicine, rocatinlimab, for adults with moderate to severe eczema (atopic dermatitis). Researchers want to see if it helps reduce skin symptoms like itching and redness, compared to a dummy treatment, over 24 weeks.
Poland · Netherlands · Portugal - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
This study is testing a new medicine, rocatinlimab, for teenagers with moderate to severe eczema (atopic dermatitis). Researchers want to see if it's safe and helps improve their skin and reduce itching over 52 weeks, compared to a dummy treatment.
Croatia · Italy · Hungary - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)
This study is looking into a new treatment called rocatinlimab for adults with moderate to severe eczema. It wants to see if this new medicine, when used with usual eczema creams, can help clear up skin and reduce itching compared to a dummy treatment.
Italy · Netherlands · Slovakia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at the long-term safety and effectiveness of a new medicine called Lebrikizumab for adults and teenagers with moderate to severe eczema (atopic dermatitis). We want to see how well it works over two years and if there are any side effects.
Germany · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
This study is testing a new tablet called BP1.7881 for moderate to severe eczema in adults. We want to see if it helps improve skin symptoms and itching, compared to a dummy tablet, over 12 weeks.
Germany · Poland · France - ongoing, recruitingHuman Pharmacology (Phase I)- Other
C5041034 - A Phase 1, Open-Label, Randomized, Single Dose, Crossover Study to Estimate the Relative Bioavailability of Etrasimod (PF-07915503) Mini Tablets in Water and 3 Food Vehicles Compared to the Etrasimod (PF-07915503) Clinical IR Tablets Under Fasted Conditions, and to Evaluate Mini Tablet Palatability in Healthy Adult Participants
This study looks at how a new medicine, etrasimod, is absorbed by the body. We're comparing different forms of the medicine in healthy adults to see which works best and is easiest to take, especially for conditions like ulcerative colitis.
Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis; J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking into new ways to treat adults with moderate to severe eczema (atopic dermatitis). Researchers want to see how well a new medicine, LY3454738, works and if it's safe. They will compare it to a dummy treatment over 52 weeks.
Italy · Poland · Hungary - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
This study is looking at a new medicine called BMS-986326 for people with eczema (atopic dermatitis). Researchers want to see how a single dose works in the body at two different dose levels. It's an early-stage study to understand the medicine better.
Czechia · Germany · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)
This study is testing a new medicine, NM26-2198, for people with eczema (atopic dermatitis). It's a very early study to see if the medicine is safe and how it works in the body, both in healthy people and those with moderate to severe eczema.
Germany · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD)
This study is testing a new medicine, LEO 138559, for moderate to severe eczema in adults. We want to see if different doses are safe and if they help improve eczema symptoms over 16 weeks compared to a dummy medicine.
Romania · Germany · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
This study looks at a new treatment called Lebrikizumab for adults and teenagers with moderate to severe eczema. We want to see how well it works and if it's safe. The main goal is to find out how many people see a big improvement in their eczema after 24 weeks.
Germany · Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Sub Study to Learn About the Study Medication Called Etrasimod Tablets in a Hybrid Decentralized Clinical Trial Setting
This study is looking into a new medicine called etrasimod. It aims to understand how etrasimod works in the body for conditions like ulcerative colitis, alopecia areata, eczema, and a specific gut issue. It's a very early stage study, done partly from home.
Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised controlled trial of a moisturiser for treatment of dry skin in atopic dermatitis: effect on the skin barrier in adults with a history of eczema
This study is looking at how well different moisturisers work to improve dry skin in adults who have a history of eczema. Researchers want to see if a new moisturiser can strengthen the skin's protective barrier compared to other treatments or no treatment at all.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, ANB032, for people with moderate to severe eczema (atopic dermatitis). We want to see if it makes skin better and if it's safe to use, compared to a dummy treatment.
Poland · Czechia - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
This study is testing a new medicine called IMG-007 for adults with moderate to severe eczema (atopic dermatitis). We want to see if it's safe, how it moves through the body, and if it helps improve skin. Some people will get the medicine, others a dummy treatment.
Germany · Poland - ongoing, recruitingTherapeutic confirmatory (Phase III)
I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at a new medicine called Baricitinib for children and teenagers with moderate to severe eczema. It wants to see if the medicine is safe and effective in helping their skin get better, compared to a dummy pill.
Hungary · Czechia · Poland - recruitingPHASE1
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
This study compares a new medicine, CKD-706, with an existing one, Dupixent, in healthy adults. We're looking at how the body handles them, their effects, and safety to see if CKD-706 works similarly to Dupixent for conditions like eczema.
Germany · United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
This study is testing a new medicine, eblasakimab, for adults with moderate to severe eczema (atopic dermatitis) who have already tried a medicine called dupilumab. Researchers want to see if it helps improve their skin and is safe.
Poland · Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
This study is comparing two versions of a drug called upadacitinib. It's to check if a new version works the same way in the body as the existing one. Healthy adults volunteer for this study.
Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.
This study compares a new version of upadacitinib (a medicine for arthritis and other conditions) from Sun Pharma with the existing Rinvoq medicine. Doctors want to check if both versions work the same way in healthy adults after they’ve eaten.
Romania - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
This study compares two versions of a 15mg upadacitinib tablet in healthy adults. It's to see if a new tablet works the same way in the body as an existing one, for conditions like rheumatoid arthritis and Crohn's disease.
Romania - ongoing, recruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
This study is testing a new medicine, SCD-044, for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if different doses of this medicine are safe and help improve eczema symptoms by a lot.
Poland · Estonia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
This study is looking into a new medicine called Nemolizumab for children aged 2 to 11 who have moderate to severe eczema. It aims to see how safe the medicine is, how well it works, and how the body handles it. It's an important step in finding new ways to help children with eczema.
Hungary · Spain · Poland - active not recruitingPHASE2
A Study Evaluating APG777 in Atopic Dermatitis
This study is looking at a new medicine called APG777 for moderate to severe eczema (atopic dermatitis). Researchers want to see if it's safe and helps improve symptoms compared to a dummy medicine. It involves testing different strengths of APG777.
United States · Canada · Czechia - recruitingPHASE2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This study is looking into new ways to treat moderate to severe atopic dermatitis (eczema). It will test a new medicine called GHZ339 to see if it's safe and effective for adults. We want to find better options for people living with this skin condition.
United States · Argentina · Canada - active not recruitingPHASE3
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
This study looks at how well a new medicine, lebrikizumab, works and if it's safe for teenagers and adults with moderate to severe eczema. It wants to see if the medicine can improve skin symptoms over 24 weeks.
Germany · Netherlands · United Kingdom - recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
This study looks at how well a new medicine, nemolizumab (Nemluvio®), works for teenagers and adults with moderate to severe eczema in real-life settings. Doctors will check progress, and patients will share how they feel about their symptoms over about 12 months.
United States · Germany · United Kingdom - recruiting
Characterisation of Skin Microstructure Under Normal and Atrophied States
This study looks at how healthy skin is structured and how it changes in people with eczema who have used steroid creams for a long time. It uses a special light scan to see inside the skin without needles, aiming to understand the effects of treatments better.
United Kingdom - active not recruitingPHASE3
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
This study looks at the long-term effects of a new medicine, rocatinlimab, for teenagers and adults with moderate to severe eczema. It checks how safe and well-tolerated the medicine is, and if it continues to help over time.
United States · Argentina · Australia - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema
This study is looking at a new cream, RLS-1496, for people who have psoriasis or eczema. It's the very first time this cream is being tested in humans to see if it's safe and how it works. We want to understand if it could help these skin conditions.
Netherlands - authorisedTherapeutic exploratory (Phase II)
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
This study is looking at a new medicine, IMG-007, for adults with moderate to severe eczema (atopic dermatitis). It aims to find the right dose and see how well it works and if it's safe over 20 weeks. Doctors will check how much eczema improves.
Czechia · Spain · Germany - authorisedHuman Pharmacology (Phase I)- First administration to humans
BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis
This study is testing a new medicine, BBT001, for eczema (atopic dermatitis). It's a very early stage trial, looking at how the medicine works and if it's safe in healthy people and those with eczema.
Poland - authorisedTherapeutic use (Phase IV)
An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
This study is looking at how a new medicine, lebrikizumab, helps adults with moderate to severe eczema get better. It will check if the medicine improves skin and makes it stronger over 24 weeks. This is a real-world study, meaning it's done after the medicine has been approved.
Sweden